Tag: Oncology treatment

Amgen Announced Precision Medicine Collaboration in Oncology with Syapse

amgen
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precision medicine collaboration in oncology. Und...

Bayer and Orion nmCRPC Drug Got Priority Review

Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review to darolutamide for the treatment of non-metastatic castration...

AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma

lab research
AVEO Oncology today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial launch in Spain of F...

Russian Biologists Show Benefits of Individual Approaches in Cancer Therapy

A team of biologists from Sechenov First Moscow State Medical University and Lobachevsky University (Nizhny Novgorod) analyzed available methods of targeted drug delivery to malignant tumors. Individu...

New Class of Drugs to Stop Growing of Ovarian Cancer Cells

A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing. The Cancer Research UK and Wellcome Trust funded study,...

Research of New Treatment for Pediatric Brain Tumors

A new combination treatment aimed at resistant and recurrent low-grade gliomas slowed tumor growth and killed tumor cells in laboratory and mouse models. Researchers at the Johns Hopkins Kimmel Can...

New Technology for Detecting Early Cancer

New technology could one day enable doctors to detect cancer almost immediately, even in the very early stages, by analyzing the different proteins expressed on cancer cells. After using near infra...

Epigenetic Protein Could Be New Therapeutic Target in AML

A new study in the UK has shown that EZH2, an epigenetic protein, can potentially be a new therapeutic target for the treatment of acute myeloid leukemia (AML). A group of researchers at the Cambri...

Promicing Lung Cancer Treatment Will Be Available on NHS

NICE has today published draft final guidance recommending durvalumab (Imfinzi, AstraZeneca). It will be made available on the NHS in England immediately for people with locally advanced unresectab...

Kazakhstan to Boost Support Early Cancer Diagnosis and Treatment

Kazakhstan will establish molecular genetic laboratories in its effort to boost support for early cancer diagnosis and treatment, said Minister of Healthcare Yelzhan Birtanov at the recent Mazhilis (l...

Latvian Drug Failed UK Independent Laboratory Test

Rigvir, a Latvia-invented injectable cancer drug, finds itself at the center of fresh controversy after LTV investigative show De Facto revealed vials of Rigvir virus sold to patients appeared to be l...

LCB Partners with Takeda in Immuno-Oncology Field

LegoChem Biosciences, Inc. (LCB) announced that it has entered a research collaboration and license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for the development of antibody-drug...

LG Chem and PDC*line to Develop New Class of Antigen

PDC*line Pharma, a biotech company developing a new class of potent and scalable antigen presenting cell, based on a proprietary cell line of Plasmacytoid Dendritic cells (PDC*line), announces that it...

Pfizer and Merck Cease Phase III Study for Treatment Ovarian Cancer

Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. announced the discontinuation of the ongoing Phase III JAVELIN Ovarian...

Lonza and Largest Mideast Hospital Facilitate Patient Access to Immunotherapies

Collaboration to assess automated CAR-T cell therapy manufacturing at the point-of-care. Sheba Medical Center at Tel Hashomer, the largest hospital in Israel and the Middle East region, and Swiss-b...

FDA Approved Use of Tecentriq with Chemotherapy

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) tr...